VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
MRKMerck & Co., Inc.
$113.87$281.2B
Research
OverviewAnalysisShould I Buy?
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksMRKP/E History

MRK logoMerck & Co., Inc. (MRK) P/E Ratio History

Undervalued

Trading at 15.6x vs 5Y avg 68.8x · 45th percentile · Below historical baseline · Data 1990–2025

Current P/E (TTM)
15.6x
-77% vs 5Y avg
5Y Avg P/E
68.8x
Median 20.8x
5Y Percentile
45th
Mid-range
PEG Ratio
0.74
Growth supports price
5-Year P/E Range
15.6x
Min11.1xMedian20.8xMax778.7x
TTM EPS$7.34
Price$113.87
Earnings Yield6.39%
EPS Growth (1Y)8.0%
EPS Growth (5Y)21.2%

Loading P/E history...

P/E Ratio Analysis

As of June 21, 2026, Merck & Co., Inc. (MRK) trades at a price-to-earnings ratio of 15.6x, with a stock price of $113.87 and trailing twelve-month earnings per share of $7.34.

The current P/E is 77% below its 5-year average of 68.8x. Over the past five years, MRK's P/E has ranged from a low of 11.1x to a high of 778.7x, placing the current valuation at the 45th percentile of its historical range.

Compared to the Healthcare sector median P/E of 22.1x, MRK trades at a 29% discount to its sector peers. The sector includes 234 companies with P/E ratios ranging from 0.0x to 197.0x.

The PEG ratio of 0.74 (P/E divided by 8% EPS growth) suggests the stock may be undervalued relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.

Relative to the broader market, MRK trades at a notable discount to the S&P 500 median P/E of 24.4x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our MRK DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

MRK Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
15.6vs22.1
-29%
Below Sector
vs. S&P 500
15.6vs24.4
-36%
Below Market
PEG Analysis
0.74
P/E ÷ EPS Growth
PEG < 1 = Attractive
Based on 8% EPS growth (1Y)

MRK P/E vs Peers

Vaccines and plasma-derived therapies peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
PFE logoPFEPfizer Inc.
$143B18.5--4%
LLY logoLLYEli Lilly and Company
$1.0T47.81.66+96%
ABBV logoABBVAbbVie Inc.
$383B91.4--1%
BMY logoBMYBristol-Myers Squibb Company
$110B15.7-+178%
AMGN logoAMGNAmgen Inc.
$182B23.78.07+88%
JNJ logoJNJJohnson & Johnson
$550B39.4--58%
AZN logoAZNAstraZeneca PLC
$271B26.71.23+191%
GSK logoGSKGSK plc
$102B6.9Lowest0.48+348%
NVO logoNVONovo Nordisk A/S
$192B12.20.59+2%
GILD logoGILDGilead Sciences, Inc.
$154B18.30.14Best+1684%Best

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

MRK Historical P/E Data (1990–2025)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2025 Q4Dec 31 2025$105.26$7.2814.5x-52%
FY2025 Q3-$83.93$7.5711.1x-63%
FY2025 Q2Jun 30 2025$79.16$6.4912.2x-60%
FY2025 Q1Mar 31 2025$89.76$6.8713.1x-57%
FY2024 Q4-$99.48$6.7314.8x-51%
FY2024 Q3Sep 30 2024$113.56$4.7723.8x-21%
FY2024 Q2Jun 30 2024$123.80$5.3923.0x-24%
FY2024 Q1Mar 31 2024$131.95$0.90146.6x+386%
FY2023 Q4Dec 31 2023$109.02$0.14778.7x+2483%
FY2023 Q3Sep 30 2023$102.95$1.8057.2x+90%
FY2023 Q2Jun 30 2023$115.39$1.2294.6x+214%
FY2023 Q1Mar 31 2023$106.39$5.1220.8x-31%
FY2022 Q4Dec 31 2022$110.95$5.7119.4x-36%
FY2022 Q3Sep 30 2022$86.12$6.0114.3x-52%
FY2022 Q2-$91.17$6.5314.0x-54%
FY2022 Q1-$82.05$5.5914.7x-51%
FY2021 Q4Dec 31 2021$76.64$5.1414.9x-51%
FY2021 Q3-$75.11$2.8426.4x-12%
FY2021 Q2Jun 30 2021$77.77$2.2035.4x+17%
FY2021 Q1Mar 31 2021$73.51$2.7726.5x-12%
FY2020 Q4-$78.00$2.7828.1x-7%
FY2020 Q3Sep 30 2020$79.09$4.5217.5x-42%
FY2020 Q2-$73.74$4.1018.0x-40%
FY2020 Q1-$73.36$3.9518.6x-38%
FY2019 Q4-$86.72$3.8122.8x-24%
FY2019 Q3Sep 30 2019$80.27$3.5822.4x-26%
FY2019 Q2Jun 30 2019$79.95$3.5722.4x-26%
FY2019 Q1Mar 31 2019$79.30$3.1725.0x-17%
FY2018 Q4Dec 31 2018$72.86$2.3231.4x+4%
FY2018 Q3Sep 30 2018$67.64$1.3151.6x+71%
FY2018 Q2Jun 30 2018$57.88$0.56103.4x+243%
FY2018 Q1Mar 31 2018$51.94$0.6481.2x+169%
FY2017 Q4Dec 31 2017$53.65$0.9357.7x+91%
FY2017 Q3Sep 30 2017$61.05$1.6736.6x+21%
FY2017 Q2Jun 30 2017$61.11$2.4724.7x-18%
FY2017 Q1Mar 31 2017$60.59$2.1927.7x-8%
FY2016 Q4Dec 31 2016$56.13$2.0327.7x-8%
FY2016 Q3Sep 30 2016$59.51$1.9630.4x+1%
FY2016 Q2-$54.93$1.8230.2x+0%
FY2016 Q1-$50.45$1.6331.0x+3%
FY2015 Q4-$50.37$1.5632.3x+7%
FY2015 Q3Sep 30 2015$47.09$3.7512.6x-58%
FY2015 Q2-$54.28$3.4215.9x-47%
FY2015 Q1-$54.81$3.8614.2x-53%
FY2014 Q4Dec 31 2014$54.15$4.1013.2x-56%
FY2014 Q3-$56.52$1.8231.1x+3%
FY2014 Q2Jun 30 2014$55.16$1.8929.2x-3%
FY2014 Q1Mar 31 2014$54.13$1.5135.8x+19%
FY2013 Q4-$47.72$1.4632.7x+8%
FY2013 Q3Sep 30 2013$45.40$1.6627.3x-9%
FY2013 Q2Jun 30 2013$44.29$1.8424.1x-20%
FY2013 Q1Mar 31 2013$42.15$2.1020.1x-33%
FY2012 Q4Dec 31 2012$39.04$2.1418.2x-39%
FY2012 Q3Sep 30 2012$43.00$2.1719.8x-34%
FY2012 Q2Jun 30 2012$39.81$2.1618.4x-39%
FY2012 Q1Mar 31 2012$36.62$2.2516.3x-46%
FY2011 Q4Dec 31 2011$35.95$2.0317.7x-41%
FY2011 Q3Sep 30 2011$31.18$1.3722.8x-24%
FY2011 Q2-$33.65$0.9336.2x+20%
FY2011 Q1-$31.48$0.5260.5x+101%
FY2010 Q4Dec 31 2010$34.37$0.27127.3x+322%
FY2010 Q3-$35.10$3.5210.0x-67%
FY2010 Q2Jun 30 2010$33.34$5.026.6x-78%
FY2010 Q1Mar 31 2010$35.61$5.526.5x-79%
FY2009 Q4-$34.84$6.105.7x-81%
FY2009 Q3Sep 30 2009$30.16$3.798.0x-74%
FY2009 Q2-$26.66$2.699.9x-67%
FY2009 Q1-$25.51$2.779.2x-69%
FY2008 Q4Dec 31 2008$28.99$3.628.0x-73%
FY2008 Q3-$30.09$2.1014.3x-52%
FY2008 Q2Jun 30 2008$35.94$2.2915.7x-48%
FY2008 Q1Mar 31 2008$36.19$2.2416.2x-46%
FY2007 Q4Dec 31 2007$55.41$1.5036.9x+23%
FY2007 Q3Sep 30 2007$49.29$2.4720.0x-34%
FY2007 Q2Jun 30 2007$47.49$2.2021.6x-28%
FY2007 Q1Mar 31 2007$42.12$2.1219.9x-34%
FY2006 Q4Dec 31 2006$41.57$2.0320.5x-32%
FY2006 Q3Sep 30 2006$39.95$2.3217.2x-43%
FY2006 Q2Jun 30 2006$34.74$2.5413.7x-55%
FY2006 Q1Mar 31 2006$33.59$2.1815.4x-49%
FY2005 Q4Dec 31 2005$30.33$2.1114.4x-52%
FY2005 Q3Sep 30 2005$25.95$2.1012.4x-59%
FY2005 Q2-$29.37$2.0514.3x-52%
FY2005 Q1-$30.87$2.5112.3x-59%
FY2004 Q4Dec 31 2004$30.65$2.6211.7x-61%
FY2004 Q3-$31.47$2.7411.5x-62%
FY2004 Q2Jun 30 2004$45.29$2.9615.3x-49%
FY2004 Q1Mar 31 2004$42.14$3.0014.0x-53%
FY2003 Q4Dec 31 2003$44.05$3.0314.5x-52%
FY2003 Q3-$48.27$3.2514.9x-51%
FY2003 Q2Jun 30 2003$57.74$3.2617.7x-41%
FY2003 Q1Mar 31 2003$52.23$3.2016.3x-46%
FY2002 Q4-$53.98$3.1517.1x-43%
FY2002 Q3Sep 30 2002$43.59$3.1313.9x-54%
FY2002 Q2Jun 30 2002$48.29$3.1415.4x-49%
FY2002 Q1Mar 31 2002$54.90$3.1517.4x-42%
FY2001 Q4Dec 31 2001$56.07$3.1517.8x-41%
FY2001 Q3Sep 30 2001$63.50$3.1020.5x-32%
FY2001 Q2Jun 30 2001$60.94$3.0420.0x-33%
FY2001 Q1Mar 31 2001$72.37$2.9924.2x-20%
FY2000 Q4Dec 31 2000$89.27$2.9130.7x+2%
FY2000 Q3Sep 30 2000$70.98$2.8225.2x-16%
FY2000 Q2Jun 30 2000$73.06$2.6827.3x-10%
FY2000 Q1Mar 31 2000$59.24$2.5623.1x-23%
FY1999 Q4Dec 31 1999$64.06$2.4725.9x-14%
FY1999 Q3-$61.80$2.3826.0x-14%
FY1999 Q2Jun 30 1999$70.20$2.3030.5x+1%
FY1999 Q1Mar 31 1999$76.40$2.2334.3x+14%
FY1998 Q4-$70.50$2.1732.5x+8%
FY1998 Q3Sep 30 1998$61.77$2.1029.4x-2%
FY1998 Q2-$63.77$2.0331.4x+4%
FY1998 Q1-$61.11$1.9631.2x+3%
FY1997 Q4Dec 31 1997$50.54$1.8926.7x-11%
FY1997 Q3-$47.68$1.8026.5x-12%
FY1997 Q2Jun 30 1997$48.81$1.7228.4x-6%
FY1997 Q1Mar 31 1997$40.20$1.6424.5x-19%
FY1996 Q4-$37.96$1.5824.0x-20%
FY1996 Q3Sep 30 1996$33.55$1.5022.4x-26%
FY1996 Q2Jun 30 1996$30.81$1.4421.4x-29%
FY1996 Q1Mar 31 1996$29.68$1.4021.2x-30%
FY1995 Q4Dec 31 1995$31.29$1.3623.0x-24%
FY1995 Q3Sep 30 1995$26.70$1.3320.1x-33%
FY1995 Q2Jun 30 1995$23.42$1.2918.2x-40%
FY1995 Q1Mar 31 1995$20.32$1.2516.3x-46%
FY1994 Q4Dec 31 1994$18.18$1.2115.0x-50%
FY1994 Q3Sep 30 1994$16.98$1.1914.3x-53%
FY1994 Q2-$14.18$1.1911.9x-60%
FY1994 Q1-$14.18$0.9614.8x-51%
FY1993 Q4Dec 31 1993$16.40$0.9617.1x-43%
FY1993 Q3-$14.66$0.7120.6x-32%
FY1993 Q2Jun 30 1993$17.22$0.6825.3x-16%
FY1993 Q1Mar 31 1993$16.87$0.8918.9x-37%
FY1992 Q4-$20.68$0.8723.7x-21%
FY1992 Q3Sep 30 1992$21.22$1.0520.2x-33%
FY1992 Q2-$23.24$1.0123.0x-24%
FY1992 Q1-$23.38$0.9624.4x-19%
FY1991 Q4-$26.46$0.9228.8x-5%
FY1991 Q3Sep 30 1991$20.68$0.8823.5x-22%
FY1991 Q2Jun 30 1991$18.44$0.8422.0x-27%
FY1991 Q1Mar 31 1991$16.76$0.8020.9x-30%
FY1990 Q4Dec 31 1990$14.27$0.7618.8x-38%
FY1990 Q3Sep 30 1990$12.10$0.7316.6x-45%

Average P/E for displayed period: 30.1x

Export Data
Consensus-Based Analysis Tools

Full Stock Analysis

Deep dive into MRK consensus models and risk factors.

View Analysis

Should I Buy MRK?

Wall Street verdict, signals, and target summaries.

See Verdict

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

36+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

MRK — Frequently Asked Questions

Quick answers to the most common questions about buying MRK stock.

What is MRK's P/E ratio?

Merck & Co., Inc. (MRK) trailing twelve-month P/E ratio is 15.6x, based on TTM diluted EPS of $7.34. The 5-year average P/E is 68.8x and the historical range spans 11.1x to 778.7x.

Is MRK stock overvalued or undervalued?

MRK trades at 15.6x P/E, below its 5-year average of 68.8x. At the 45th percentile of its historical range (11.1x–778.7x), the stock is priced at a discount to its own history.

Is MRK stock expensive?

No, MRK is not expensive on a historical basis. The current P/E of 15.6x is below the 5-year average of 68.8x and sits at the 45th percentile of its valuation range.

What is MRK's historical P/E range?

Over the past 5 years, MRK's P/E ratio has ranged from 11.1x to 778.7x, with a median of 20.8x and an average of 68.8x. The current P/E of 15.6x places the stock at the 45th percentile of this range. Full historical data spans 1990–2025.

How does MRK's P/E compare to the S&P 500?

MRK trades at 15.6x P/E versus the S&P 500 median of 24.4x. The 36% discount to the market suggests lower growth expectations or perceived higher risk.

How does MRK's valuation compare to Healthcare peers?

Merck & Co., Inc. P/E of 15.6x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is MRK's PEG ratio?

MRK PEG ratio is 0.74, based on a P/E of 15.6x and EPS growth of 8.0%. A PEG below 1.0 indicates the valuation is supported by the earnings growth rate — typically considered attractive.

What is MRK's earnings yield?

MRK earnings yield is 6.39%, the inverse of its 15.6x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

MRK P/E Ratio History (1990–2025)

Quarterly valuation multiple from closing price and trailing EPS

Current14.5x
Period Avg68.8x
Range11.1x - 778.7x
Change-46%
20 quartersMar 31, 2021 - Dec 31, 2025